Page 11234..»

Category Archives: Clinical Cardiology

Insights from the European Society of Cardiology congress | Speaking of Medicine – PLoS Blogs

Posted: September 30, 2019 at 4:44 pm

Adya Misra, Senior Editor PLOS Medicine reports from the ESC annual congress in Paris Every year approximately 30,000 researchers, medical doctors and policymakers come together to discuss the latest developments in Cardiovascular medicine. This year, Ijoined the European Society of Cardiologys (ESC) annual congress in sunny Paris to learn how the field of cardiology is evolving within the rapidly changing landscape of medicine. Continue reading

Posted in Clinical Cardiology | Comments Off on Insights from the European Society of Cardiology congress | Speaking of Medicine – PLoS Blogs

Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI – The Cardiology Advisor

Posted: at 4:44 pm

Adjunctive remote ischemic conditioning in patients undergoing treatment for ST-elevation myocardial infarction (STEMI) does not improve clinical outcomes at 12 months, according to study findings published inThe Lancet. The investigators of the prospective, single-blind,randomized controlled trial examined whether cardioprotective remote ischemicconditioning could reduce the frequency of cardiac death and hospitalizationfor heart failure at 12 months postintervention in patients with myocardialinfarction Continue reading

Posted in Clinical Cardiology | Comments Off on Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI – The Cardiology Advisor

Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF – The Cardiology Advisor

Posted: at 4:44 pm

Although dapagliflozin did not affect mean N-terminal pro b-type natriuretic peptide (NT-proBNP) levels in persons with heart failure with reduced ejection fraction (HFrEF), the proportion of patients demonstrating clinical improvements heart failure-associated health status increased, according to study results published in Circulation. Researchers assessed results from the DEFINE-HF trial, a randomized, placebo-controlled, double-blind trial of 263 individuals with HFrEF. Heart failure with reduced ejection fraction was defined as New York Heart Association class II or III, 16 weeks of diagnosed HF, left ventricular ejection fraction 40%, estimated glomerular filtration rate 30 mL/min/1.73 m, and high natriuretic peptides. Continue reading

Posted in Clinical Cardiology | Comments Off on Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF – The Cardiology Advisor

New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis – Newswise

Posted: at 4:44 pm

MEDIA CONTACT Available for logged-in reporters only Newswise SAN FRANCISCO September 27, 2019 The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems available in the United States. Continue reading

Posted in Clinical Cardiology | Comments Off on New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis – Newswise

AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy – Medscape

Posted: at 4:44 pm

SAN FRANCISCO An antithrombotic regimen that includes apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) and a P2Y12 inhibitor is effective and may be a safer option in patients with atrial fibrillation (AF) with acute coronary syndrome (ACS), a new analysis from the AUGUSTUS trial suggests. Compared with regimens that include a vitamin K antagonist (VKA), aspirin, or both, the apixaban/P2Y12 inhibitor regimen provided superior safety and similar efficacy for patients managed medically or with percutaneous coronary intervention (PCI), or who underwent elective PCI for stable coronary disease. Adding aspirin to the regimen increased major bleeding episodes but did not significantly affect ischemic outcomes. Continue reading

Posted in Clinical Cardiology | Comments Off on AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy – Medscape

Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD – The Cardiology Advisor

Posted: at 4:44 pm

The Medicines Company announced positive topline results from the phase 3 ORION-9 and ORION-10 studies for inclisiran in patients with either heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD), respectively, plus elevated low-density lipoprotein cholesterol (LDL-C) despite maximally tolerated statin therapy (with or without ezetimibe). Inclisiran is a chemically synthesized small interfering RNA (siRNA) that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA Continue reading

Posted in Clinical Cardiology | Comments Off on Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD – The Cardiology Advisor

Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy – FierceHealthcare

Posted: at 4:44 pm

Google parent company Alphabet has hired former U.S. Food and Drug Administration Commissioner Robert Califf, M.D., to lead its health strategy and policy. Continue reading

Posted in Clinical Cardiology | Comments Off on Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy – FierceHealthcare

The Heart of the Matter: Cardiovascular Fitness in Horses – United States Eventing Association

Posted: at 4:44 pm

Sep 30, 2019 The health and safety of our equine athletes is always our first priority, and that means making sure they are physically fit and healthy enough to compete. Frequently, focus is placed on the soundness in a horses legs and feet, but what about his heart? Continue reading

Posted in Clinical Cardiology | Comments Off on The Heart of the Matter: Cardiovascular Fitness in Horses – United States Eventing Association

Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE – BioSpace

Posted: at 4:44 pm

Sept. 27, 2019 18:30 UTC Study in The Lancet successfully demonstrated endpoints of identifying both vulnerable patients and vulnerable plaques that are at significantly higher risk for subsequent major adverse cardiovascular events BEDFORD, Mass.--(BUSINESS WIRE)-- Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced that the Lipid-Rich Plaque (LRP) Study was published online today in The Lancet. The landmark study demonstrated that near-infrared spectroscopy (NIRS) imaging of non-obstructive areas in patients undergoing cardiac catheterization and possible percutaneous coronary intervention (PCI) was safe and can aid in identifying patients and artery segments at higher risk for subsequent non-culprit major adverse cardiovascular events (NC-MACE). Continue reading

Posted in Clinical Cardiology | Comments Off on Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE – BioSpace

Off Script: The New Gatekeepers of Procedural Education – TCTMD

Posted: at 4:44 pm

SAN FRANCISCO, CA I spent my second day at TCT 2019 sampling the excellent selection of practical educational opportunities in the TCT Training Pavilion and speaking to some of the professional staff supporting industry-led training programs. The last few years have seen a proliferation in the popularity of teaching pavilions at interventional cardiology conferences in which small group skill training is taught by experienced interventionalists, usually with the use of sophisticated procedural simulators. I found myself wondering: what has led to their rise in popularity, why are they found primarily at major meetings, and do they fulfill an important need Continue reading

Posted in Clinical Cardiology | Comments Off on Off Script: The New Gatekeepers of Procedural Education – TCTMD

Page 11234..»